Polylaminin developed in the laboratory offers a new perspective for spinal cord regeneration in Brazil

Innovative research developed at Universidade Federal of Rio of Janeiro uses a network of proteins to reconnect damaged axons in the spinal cord. The substance, known as polylaminin, allows the restoration of communications between the brain and the body in cases of serious injuries. The study, led by biologist Tatiana Sampaio, has already demonstrated promising results in patients with complete paraplegia. Agência Nacional of Vigilância Sanitária approved the start of clinical trials in January 2026, marking a significant step towards evaluating safety and efficacy.

Patients who received polylaminin application reported improvements in subtle movements and control of physiological functions. Esses advances have occurred in the context of recent injuries, where rapid intervention is crucial to prevent the formation of scars in the spinal cord. The substance is produced from laminins rearranged in the laboratory, creating a structure that guides the growth of affected neurons.

Experts highlight the importance of combining treatment with intensive physiotherapy to maximize the benefits. The research, which spans almost three decades, is now seeking confirmation in controlled tests for possible inclusion in the Sistema Único of Saúde.

Development of polylaminin at UFRJ

Polylaminin emerged from studies started 27 years ago at UFRJ, focusing on the regeneration of nervous tissues. Biologist Tatiana Sampaio identified that laminins form an essential basis for axon growth, acting as a biological clue to reconnect interrupted paths. Essa simple approach, based on natural proteins, evolved into a patented formulation in partnership with the Cristália laboratory.

The first laboratory experiments confirmed the substance’s ability to promote the elongation of neurons in controlled environments. Over time, testing progressed to animal models, where functional recovery was observed in simulated injuries. The transition to human applications began with compassionate cases, authorized by Anvisa, revealing potentials that go beyond initial research expectations.

Application to patients with complete lesions

In an academic study involving eight individuals with complete spinal cord injuries, 75% of participants showed significant motor recovery. Esses results contrast with the 10% recovery reported in traditional medical literature for similar cases. Patients demonstrated skills such as moving their feet and contracting abdominal muscles, which improves their daily quality of life.

The application of polylaminin requires precise surgical intervention, performed by trained neurosurgeons. In documented examples, such as a patient treated less than 24 hours after trauma, progression led from initial movements in the big toe to independent walking with support. Tais gains depend on the absence of previous scarring in the marrow, reinforcing the need for immediate action.

Limitations and challenges in treatment

Polylaminin is not applicable to incomplete spinal cord injuries, as it may interfere with existing residual functions. Pacientes with this type of damage, who maintain some sensitivity or movement, face risks of worsening if subjected to the procedure. Além Furthermore, the substance requires rigorous post-application physiotherapy, which is not always available in remote regions of the country.

Access to specialized rehabilitation represents an obstacle for many, as seen in cases in smaller cities. Sem this support, the potential benefits of polylaminin may be limited, highlighting the need for investment in healthcare infrastructure. Research emphasizes that the combination of drug treatment and physical therapy is essential for lasting results.

Anvisa Authorization and Compassionate Use

Anvisa allowed for the compassionate use of polylaminin in situations where there are no viable alternatives, benefiting patients outside of formal clinical trials. Esse mechanism, based on compassion, has already been used in dozens of cases, with 30 judicial approvals among 55 requests. Reports include recoveries such as bladder control and knee movements, altering individuals’ autonomy.

However, experts warn of the importance of scientific rigor before expansions. Eventos adverse effects, although not directly linked to the substance in preliminary analyses, require continuous monitoring. Approval for phase 1 of clinical trials, in January 2026, involves five volunteers with acute chest injuries, aiming to evaluate safety in direct applications to the injured area.

Results observed in real cases

Diogo, victim of an electric shock followed by a fall, received polylaminin after being transferred between hospitals. Semanas later, he noticed movements in his right foot, progressing to bladder control and abdominal contractions. Sua sensitivity, initially limited to the chest, extended to the diaphragm, representing a personal milestone in recovery.

Bruno, treated in 2018 shortly after breaking his neck, went from total paralysis to walking with a cane within a year. Sua rating changed from “A” to “D”, indicating strength and sensitivity in almost all movements. Mirian, after a fracture caused by a fall on a staircase, developed reflexes and sensitivity with weekly physiotherapy sessions, illustrating the combined impact of the treatment.

These examples highlight individual variations in the response to polylaminin. Fatores how application time and adherence to rehabilitation influence outcomes, with an emphasis on early interventions to optimize axonal regeneration.

Perspectives for future clinical trials

The clinical trials approved by Anvisa will begin in March 2026, covering three phases to prove efficacy and safety. The initial phase focuses on five patients with recent injuries between T2 and T10, aged 18 to 72 years. The criteria include surgical indication within 72 hours of the trauma, ensuring ideal conditions for the substance to act.

If successful, the tests could lead to availability within five years, with integration into the SUS for broad access. The partnership between UFRJ and Cristália speeds up the process, but challenges such as the loss of international patents due to funding cuts in 2015-2016 highlight vulnerabilities in national research funding.

Controversies and expert opinions

Some doctors express caution about mass application without conclusive data. Representantes from AACD warn of risks of untraceable adverse events in uncontrolled uses. Quatro deaths among treated patients did not show a correlation with polylaminin, but reinforce the need for rigorous studies.

Scientific entities call for moderation in media exposure, avoiding unrealistic expectations. Judicialization, common in 55 cases, reflects the urgency of patients, but can compromise technical rigor. Pesquisadores argue that the substance represents a game changer in the treatment of spinal cord injuries, balancing innovation with prudence.

Extraction of polylaminin and biological origin

Polylaminin is derived from laminins present in the human placenta, rearranged to form a stable protein network. Esse laboratory process guarantees purity and effectiveness, avoiding immunological rejections. Production by Cristália follows regulatory standards, preparing for larger scales if testing progresses.

Preliminary studies confirm that the substance acts as a biological scaffold, guiding neuronal growth without additional invasive interventions. Sua compatibility with the nervous system makes it a promising candidate for regenerative therapies, expanding applications beyond spinal cord injuries.

Importance of time in intervention

The effectiveness of polylaminin critically depends on the interval between trauma and application, ideally within three days. Nesse period, the medulla does not yet form scars that block axonal regeneration. Late Aplicações reduces benefits, as seen in comparisons between early and late cases.

Neurosurgeons travel to perform procedures in different regions, exemplifying the logistics involved. At airports like Campinas, teams travel to cities like Campo Grande, ensuring timely access. Essa mobility highlights the commitment to urgent interventions.

Access to rehabilitation as a barrier

Many patients face post-treatment difficulties due to the shortage of qualified rehabilitation centers. In locations such as Nova Friburgo, the lack of structure limits the gains of polylaminin. Especialistas from UFRJ emphasize that investments in infrastructure are as crucial as the development of the substance.

Intensive physiotherapy programs, carried out six times a week, enhance recovery, as in cases in Londrina. The expansion of services by the SUS could democratize benefits, aligning research with health equity.

Partnerships and research funding

The collaboration between UFRJ and Cristália made the national patent viable, despite international losses due to budget cuts. Verbas interruptions in 2015-2016 impacted the global record but did not halt local progress. Ministério of Saúde supports the move forward, announcing approvals in conjunction with Anvisa.

These partnerships strengthen Brazilian research, positioning the country in innovations in neuroscience. The focus on accessible therapies reflects national priorities, with the potential for knowledge export if trials confirm initial results.

Potential impact on patient autonomy

Treated patients reported not only movement, but greater independence in daily activities. From passively pedaling bicycles to standing with support, advances change routines. Controlling functions such as the bladder reduces secondary complications, improving overall well-being.

These improvements, observed in academic studies, suggest a path to reducing dependencies on ongoing care. Integration with assistive technologies could amplify these effects, offering holistic solutions for spinal cord injuries.

Regulatory advances in 2026

In January 2026, Ministério of Saúde and Anvisa announced approval for clinical studies, representing a regulatory milestone. Minister Alexandre Padilha highlighted the potential for the SUS, expanding assistance to patients with spinal cord injuries. The decision allows tests on specific volunteers, prioritizing acute injuries.

This progression accelerates development, with subsequent phases designed for efficacy in larger groups. Regulatory rigor ensures that only robust data guides final approval, protecting the population.

Expectations for Broad Availability

If the three phases of testing are completed successfully, polylaminin could be accessible within five years. The desire to be absorbed by the SUS aims to benefit all Brazilians, regardless of region. Pesquisadores project scalability in production, meeting the growing demand for regenerative therapies.

The substance, developed from accessible biological sources, promises viable costs for public health systems. Essa vision aligns innovation with social inclusion, transforming academic research into practical solutions.

Polylaminin represents an advance in nerve regeneration, with potential applications in acute injuries. Desenvolvida at UFRJ, the substance reconnects damaged axons, allowing motor recovery in 75% of the cases studied. Anvisa authorized clinical trials in January 2026, focusing on safety for five patients with recent trauma. Compassionate use has already benefited dozens via court decisions, but experts urge caution to avoid risks without scientific control. The ideal application occurs within 72 hours post-injury, before spinal healing. Fisioterapia intensive care is essential, highlighting challenges in accessing rehabilitation. Parcerias with Cristália guarantee production, despite loss of international patent due to funding cuts. Resultados include subtle movements, bladder control, and expanded sensitivity. Controvérsias arise about early judicialization, with scientific entities defending technical rigor. The potential for SUS promises to democratize treatment, aligning Brazilian science with public health.

Innovations in Brazilian neuroscience

Research at UFRJ integrates molecular biology knowledge with clinical applications, positioning Brasil in regenerative advances. Polylaminin, extracted and rearranged from placental laminins, offers a non-invasive approach to neuronal repair. Estudos preliminaries in animals paved the way for humans, confirming initial safety.

Specialists such as itinerant neurosurgeons facilitate applications in multiple cities, overcoming geographic barriers. Essa mobility, combined with regulatory approvals, accelerates access to innovations. The focus on chest injuries in initial trials refines protocols for future expansions.

Entities such as AACD contribute perspectives on rehabilitation, integrating treatment into existing programs. Interdisciplinary collaboration strengthens credibility, preparing for global impacts in neuroscience.

Integration with the SUS aims for equity, reducing health inequalities. Investimentos in continuous research guarantees sustainability, avoiding interruptions like those of 2015-2016.